Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregory Swor

Urogynecology and Reconstructive Pelvic Surgery Sarasota, FL Medical Doctor

NPI 1447439245 CMS profile 201328

1900 S Tuttle Ave, Sarasota, FL 34239

Open in the dashboard

General payments

$6,573

181 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$5

5 holdings reported · through program year 2025

Research they led as principal investigator

$1,224,051 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Gregory Swor of Sarasota, FL is reported in the CMS Open Payments database as having received $6,573 across 181 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,224,051 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $5 across 5 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 70th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $486 16
2024 General $333 16
2023 General $601 25
2022 General $1,783 41
2021 General $1,163 25
2020 General $409 22
2019 General $1,799 36
2024 Ownership $1 1
2023 Ownership $1 1
2022 Ownership $1 1
2021 Ownership $1 1
2020 Ownership $1 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Swor
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Gregory Swor were reported at $486. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Gregory Swor Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $1,799 $358 $132–$1,270 $163
2020 $409 $198 $86–$642 $114
2021 $1,163 $361 $118–$1,182 $132
2022 $1,783 $410 $128–$1,175 $149
2023 $601 $434 $152–$1,344 $160
2024 $333 $494 $193–$1,331 $164
2025 $486 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CONMED Corporation $2,120 5 payments
  2. AbbVie, Inc. $531 24 payments
  3. Cytyc Surgical Products, LLC $450 1 payment
  4. Bolder Surgical LLC $316 2 payments
  5. Myovant Sciences Inc. $271 10 payments
  6. Hologic, LLC $242 13 payments
  7. Astellas Pharma US Inc $241 13 payments
  8. TherapeuticsMD, Inc. $213 9 payments
  9. Sumitomo Pharma America, Inc. $198 10 payments
  10. Baxter Healthcare $186 2 payments
  11. Other $1,806 92 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,751 171 payments
  2. Consulting Fee $2,450 4 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $300 1 payment
  4. Education $73 5 payments
Products named General payments · program years 2019–2025
  1. AirSeal $1,120 3 payments
  2. CONMED HANDHELD INSTRUMENTS $1,000 2 payments
  3. MYFEMBREE $424 18 payments
  4. JustRight Sealer and CoolSeal Sealer $300 1 payment
  5. CoolSeal Generator $300 1 payment
  6. JustRight Reload $300 1 payment
  7. JustRight Stapler $300 1 payment
  8. 5mm Tissue Retrieval System $300 1 payment
  9. LO LOESTRIN FE $250 13 payments
  10. ORILISSA $235 13 payments
  11. Other $4,127 173 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

669

Median for Obstetrics & Gynecology: 65

Drug cost

$41,550

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

52.9%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 214 $12,136
Premarin Estrogens, Conjugated Brand 16 $7,543
Estradiol (Twice Weekly) Estradiol Brand 71 $6,663
Progesterone Progesterone, Micronized Brand 154 $5,189
Vagifem Estradiol Brand 12 $2,961
Dotti Estradiol Brand 15 $2,720
Estradiol (Once Weekly) Estradiol Brand 37 $2,402
Metronidazole Generic 17 $720
Valacyclovir Valacyclovir Hcl Brand 27 $569
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 22 $242

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$132,989

Medicare's payments for the services billed

Medicare patients

583

Average age 75

Services billed

1,915

583 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 53%
Osteoporosis 35%
Ischemic heart disease 20%
Depression 19%
Cancer 17%
Diabetes 15%
Atrial fibrillation 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $84
$84 — —
ABRYSVO
  • PFIZER INC. $43
$43 — —
MYFEMBREE
  • Sumitomo Pharma America, Inc. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

181 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record